Ceyhan Kutlu

Publications (2)3.41 Total impact

• Article: The effect of methylprednisolone treatment on cerebral reactivity in patients with multiple sclerosis.

  Serhat Ozkan, Nevzat Uzuner, Ceyhan Kutlu, Demet Ozbabalik, Gazi Ozdemir
  [show abstract] [hide abstract]
  ABSTRACT: We assessed the effect of intravenous high-dose methylprednisolone (IVMP) on cerebral reactivity in multiple sclerosis (MS) patients during exacerbations by means of functional transcranial Doppler imaging. Forty-eight clinically defined MS patients were evaluated with visual evoked potentials (VEP) and functional transcranial Doppler sonography (TCD) of both posterior cerebral arteries before and after 5 days of 1000 mg IVMP. After treatment, mean Expanded Disability Status Scale score, mean blood flow velocities and mean blood flow velocities at rest and at stimulation, significantly decreased (p < 0.0001, for each). The change in cerebral blood flow velocity ratio (CBFv) with visual stimulation after treatment increased slightly (p = 0.20). All TCD parameters were not significantly correlated with VEP changes. In conclusion, we observed significant changes in CBFv with a non-significant increase in vascular reactivity after treatment with IVMP in exacerbations of MS. Case-control studies are necessary to draw conclusions regarding the beneficial effects of IVMP treatment.
  Journal of Clinical Neuroscience 03/2006; 13(2):214-7. · 1.25 Impact Factor
• Article: Plasma homocysteine levels in pergolide-treated Parkinson disease patients.

  Serhat Ozkan, Omer Colak, Ceyhan Kutlu, Melek Ertan, Ozkan Alatas
  [show abstract] [hide abstract]
  ABSTRACT: Hyperhomocysteinemia is as a risk factor for increased vascular disease in l-dopa-treated Parkinson disease (PD) patients. This effect of l-dopa is associated with the metabolism of l-dopa by methylation. This study aimed to assess the effect of pergolide on plasma homocysteine levels. Plasma homocysteine levels were compared between PD patients treated with pergolide as monotherapy, with l-dopa as monotherapy, or with an l-dopa and pergolide combination and compared with controls. Plasma homocysteine levels were significantly higher in the l-dopa monotherapy group, and there were no significant differences for the pergolide treatment groups. Pergolide can be beneficial for increased plasma homocysteine levels.
  Clinical Neuropharmacology 27(4):163-5. · 2.17 Impact Factor